Aurinia Pharma Reaffirms LUPKYNIS Safety And Efficacy Following Retracted FDA Official's Post

Aurinia Pharmaceuticals (AUPH) experienced significant stock volatility following a now-retracted LinkedIn post by an FDA official questioning the safety and efficacy of its approved drug, LUPKYNIS (voclosporin), citing 'significant toxicity.' Aurinia promptly defended the drug's favorable benefit/risk profile, referencing its full FDA approval in 2021 and a recent April 2024 approval for long-term use, both supported by extensive clinical trial data. The FDA's Center for Drug Evaluation and Research (CDER) will now evaluate the surrogate endpoints used for LUPKYNIS's approval, indicating potential heightened regulatory scrutiny.

Analysis

Aurinia Pharmaceuticals (AUPH) experienced significant share price volatility following a retracted social media post from an FDA official that questioned the safety and efficacy of its key drug, LUPKYNIS (voclosporin). The stock reacted with a 15.83% decline during regular trading, closing at $11.06, before partially recovering 7.32% in after-hours activity. The official's post alleged "significant toxicity" and a lack of positive patient impact, prompting a swift defense from Aurinia. The company reaffirmed its confidence in the drug's favorable benefit/risk profile, citing its full FDA approval in January 2021 based on the AURORA 1 clinical trial, and a subsequent supplementary approval in April 2024 for long-term use, which was supported by three-year data from the AURORA 2 study. The most critical development, however, is the stated intention of the FDA's Center for Drug Evaluation and Research (CDER) to evaluate the surrogate endpoints used for the drug's approval. This introduces a tangible regulatory overhang and a period of uncertainty, transcending the initial social media incident and creating a direct conflict between the drug's established approval history and new potential regulatory scrutiny.

Key Decisions for Investors

• Investors should recognize the heightened regulatory risk now attached to Aurinia, as the FDA's evaluation of LUPKYNIS's surrogate endpoints creates a significant forward-looking overhang that could impact the drug's long-term standing.
• The sharp 15.83% sell-off followed by a 7.32% after-hours recovery indicates extreme event-driven volatility; positions should be managed with caution until the scope and potential outcome of the CDER's evaluation become clearer.
• Consider the company's robust defense, which is supported by two large-scale clinical trials and recent FDA approvals for long-term use, as a potential counterpoint to the negative sentiment, though this may not be sufficient to offset the new regulatory uncertainty in the near term.